EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

TROP2 immunoreactivity in pulmonary large cell neuroendocrine carcinoma

Michael Minkley iD, Kashif Ravasia, Thi Nghiem, Dongxia Gao, Jamie Feng iD, Andrew Churg iD, Julia R Naso iD

Histopathology · 2026

DOI: 10.1111/his.70226 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Histopathology, 2026. Verfasst von Michael Minkley und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada. Hauptthemen laut MEDLINE: Carcinoma, Neuroendocrine, Antigens, Neoplasm, Biomarkers, Tumor, Carcinoma, Large Cell. Die Arbeit nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: This project received funding from the University of British Columbia Diagnostic and Molecular Pathology Residency Program..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

TROP2 antibody‐drug conjugates have shown promising anti‐tumour activity, but neither the activity of these agents nor TROP2 expression has been well studied in pulmonary large cell neuroendocrine carcinoma (LCNEC), a rare and aggressive cancer type. We aimed to (i) determine the prevalence of TROP2 immunoreactivity in LCNEC; (ii) assess whether TROP2 immunoreactivity in LCNEC is related to RB1 loss on IHC or to the presence of NSCLC or SCLC components and (iii) determine whether TROP2 immunoreactivity in LCNEC has prognostic significance.

Methods

TROP2 immunohistochemistry was performed on 58 pure LCNECs and 25 areas of LCNEC that were combined with other carcinomas, in tissue microarray format. TROP2 was scored for the percent of tumour cells staining, and with evaluation of cytoplasmic versus membranous staining, approximating a previously published predictive scoring method.

Results

TROP2 staining in ≥1% and ≥50% of LCNEC cells was present in 60% and 26% of pure LCNEC tumours, respectively. Cytoplasmic‐type staining, previously implicated in greater antibody‐drug conjugate response, was present in 48% of pure LCNEC cases. Positive TROP2 staining was less frequent in pure LCNEC than in the LCNEC component of tumours that also contained a NSCLC component (≥1%: P = 0.0087; ≥50%: P = 0.011), and ≥50% TROP2 staining in pure LCNEC was associated with retained RB1 staining on immunohistochemistry ( P = 0.032). TROP2 staining was not associated with recurrence‐free survival or disease‐specific survival outcomes.

Conclusion

Frequently positive TROP2 IHC suggests that TROP2 antibody‐drug conjugates may be potential treatments for LCNEC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, NeuroendocrineAntigens, NeoplasmBiomarkers, TumorCarcinoma, Large CellLung NeoplasmsCell Adhesion MoleculesHumansFemaleImmunohistochemistryMaleAgedMiddle AgedAged, 80 and overAdultPrognosis

Stichwörter der Autor:innen

RB1TROP2biomarkerslarge cell neuroendocrine carcinomapathology

Substanzen

TACSTD2 protein, humanAntigens, NeoplasmBiomarkers, TumorCell Adhesion Molecules

Autor:innen und Institutionen

  • Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
  • Undergraduate Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
  • Department of Clinical Research, BC Cancer, Vancouver, British Columbia, Canada.
  • Department of Medical Oncology, BC Cancer, Vancouver, British Columbia, Canada.
  • Department of Pathology and Laboratory Medicine, Vancouver General Hospital, Vancouver, British Columbia, Canada.

ORCID-Profile: Michael Minkley, Jamie Feng, Andrew Churg, Julia R Naso

Förderung

  • This project received funding from the University of British Columbia Diagnostic and Molecular Pathology Residency Program.

Zitieren

APA

Minkley, M., Ravasia, K., Nghiem, T., Gao, D., Feng, J., Churg, A., & Naso, J. R. (2026). TROP2 immunoreactivity in pulmonary large cell neuroendocrine carcinoma. Histopathology. https://doi.org/10.1111/his.70226

Vancouver

Minkley M, Ravasia K, Nghiem T, Gao D, Feng J, Churg A, et al. TROP2 immunoreactivity in pulmonary large cell neuroendocrine carcinoma. Histopathology. 2026. doi:10.1111/his.70226

BibTeX
@article{Minkley2026,
  author = {Minkley, Michael and Ravasia, Kashif and Nghiem, Thi and Gao, Dongxia and Feng, Jamie and Churg, Andrew and Naso, Julia R},
  title = {TROP2 immunoreactivity in pulmonary large cell neuroendocrine carcinoma},
  journal = {Histopathology},
  year = {2026},
  doi = {10.1111/his.70226}
}
Kostenlos starten →